A Closer Look at Accuray
by Michael Shulman
BiotechBlitz
If enough people ask you a question, you should go out and find the answer.
A few days ago I finished giving seminars at the Money Show in Orlando and four people asked me about a company I do not follow or recommend, Accuray (ARAY). After reading some and talking to others, I am still not recommending it in my service but thought you might want to take a look, in part because it was recently crushed when it reduced revenue estimates for 2008.
Accuray makes several products but its leader and growth engine is CyberKnife Robotic Radiosurgery System, used to directly target cancer tumors with narrow and powerful doses of radiation. Sales doubled in Q4, year over year, for the company but a few days ago the company reduced sales estimates for 2008 to $210 million -$230 million from $250 million-$270 million. ARAY blamed tightened credit conditions, specifically as they apply to cancer and radiation treatment centers, for slowing growth. It also earned about four cents a share.
There are two ways to look at this explanation:
First, if true, then these centers are overextended, which means there are too many of them and sales were going to slow to this segment sooner rather than later.
Reimbursement rates are too low -- probably driven by traditional radiation treatment, creating margins too low to generate the profits needed to keep credit ratings up. This situation, however, can be fixed with new reimbursement rates based on clinical data showing the treatments are more effective -- which they are for many.
The stock was crushed on the pullback in forecasts, lemming analysts reduced their ratings, and the stock, although it sports a very high P/E, (more than 50) has a modest P/S (less than 3) given the sector -- medical devices.
Bottom line: at a minimum, this is a company to watch -- despite competition from industry heavyweight Varian Medical Systems (VAR), a terrific outfit. I am waiting -- I am going to ask the ChangeWave survey group to put together a survey on what is going on inside treatment and surgical centers and we may find out more about Accuray. I do not currently own any stock in this company.
A quick note: I have been unusually busy and the market unusually ugly, prompting me to reduce the frequency of articles. They will pick up again this week. Send me an e-mail at mshulman@changewave.com if something interests you.
BioHealthInvestor.com
____________________
BiotechBlitz
If enough people ask you a question, you should go out and find the answer.
A few days ago I finished giving seminars at the Money Show in Orlando and four people asked me about a company I do not follow or recommend, Accuray (ARAY). After reading some and talking to others, I am still not recommending it in my service but thought you might want to take a look, in part because it was recently crushed when it reduced revenue estimates for 2008.
Accuray makes several products but its leader and growth engine is CyberKnife Robotic Radiosurgery System, used to directly target cancer tumors with narrow and powerful doses of radiation. Sales doubled in Q4, year over year, for the company but a few days ago the company reduced sales estimates for 2008 to $210 million -$230 million from $250 million-$270 million. ARAY blamed tightened credit conditions, specifically as they apply to cancer and radiation treatment centers, for slowing growth. It also earned about four cents a share.
There are two ways to look at this explanation:
First, if true, then these centers are overextended, which means there are too many of them and sales were going to slow to this segment sooner rather than later.
Reimbursement rates are too low -- probably driven by traditional radiation treatment, creating margins too low to generate the profits needed to keep credit ratings up. This situation, however, can be fixed with new reimbursement rates based on clinical data showing the treatments are more effective -- which they are for many.
The stock was crushed on the pullback in forecasts, lemming analysts reduced their ratings, and the stock, although it sports a very high P/E, (more than 50) has a modest P/S (less than 3) given the sector -- medical devices.
Bottom line: at a minimum, this is a company to watch -- despite competition from industry heavyweight Varian Medical Systems (VAR), a terrific outfit. I am waiting -- I am going to ask the ChangeWave survey group to put together a survey on what is going on inside treatment and surgical centers and we may find out more about Accuray. I do not currently own any stock in this company.
A quick note: I have been unusually busy and the market unusually ugly, prompting me to reduce the frequency of articles. They will pick up again this week. Send me an e-mail at mshulman@changewave.com if something interests you.
BioHealthInvestor.com
____________________
posted by Nico at
9:39 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home